Search results for "severity"

showing 10 items of 1287 documents

Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics

2017

BACKGROUND People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics. METHODS This is a cross-sectional study developed in an outpatient mental health clinic in which the preva…

AdultMalemedicine.medical_specialtyPsychosisHealth StatusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentHealth BehaviorDiseasePharmacologyRisk AssessmentSeverity of Illness IndexInjectionsHabitsYoung Adult03 medical and health sciences0302 clinical medicineCost of IllnessRisk FactorsInternal medicinePrevalencemedicineHumansImmunology and AllergyAntipsychoticLife StyleAgedMetabolic SyndromeFramingham Risk Scorebusiness.industryMental DisordersMiddle Agedmedicine.diseaseMental healthObesity030227 psychiatryCross-Sectional StudiesCardiovascular DiseasesSpainSchizophreniaDelayed-Action PreparationsFemaleMetabolic syndromebusiness030217 neurology & neurosurgeryAntipsychotic AgentsEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.

2009

AbstractBackgroundPurpose of this study was to assess subjective well-being in schizophrenia inpatients and to find variables predictive for response and remission of subjective well-being.MethodThe subjective well-being under neuroleptic treatment scale (SWN-K) was used in 232 schizophrenia patients within a naturalistic multicenter trial. Early response was defined as a SWN-K total score improvement of 20% and by at least 10 points within the first 2 treatment weeks, response as an improvement in SWN-K total score of at least 20% and by at least 10 points from admission to discharge and remission in subjective well-being as a total score of more or equal to 80 points at discharge. Logisti…

AdultMalemedicine.medical_specialtyPsychosisMedizinPersonal SatisfactionLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineMulticenter trialmedicineHumansIn patient030212 general & internal medicineSubjective well-beingPsychiatryPsychiatric Status Rating ScalesDepressionMiddle Agedmedicine.disease3. Good health030227 psychiatryPsychiatry and Mental healthTreatment OutcomeSchizophreniaPsychological well-beingQuality of LifeSchizophreniaFemaleSchizophrenic PsychologyPsychologyEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

A possible association between the CCK-AR gene and persistent auditory hallucinations in schizophrenia.

2004

AbstractRecent studies have suggested that DNA variations in the CCK-AR gene might predispose individuals to schizophrenia and particularly to auditory hallucinations (AH). The aim of this study is to assess the association between AH, using a specific scale for AH in schizophrenia (PSYRATS), and the CCK-AR polymorphism at 779 in a Spanish sample. A total of 105 DSM-IV schizophrenic patients with AH and 93 unrelated controls were studied. Twenty-two patients were considered as persistent auditory hallucinators, which showed similar clinical and demographic characteristic than patients with episodic AH, but with the exception of the PSYRATS values. The persistent AH group showed an excess of…

AdultMalemedicine.medical_specialtyPsychosisPeriodicityGenotypeHallucinationsSeverity of Illness IndexGenetic determinismLinkage Disequilibrium03 medical and health sciences0302 clinical medicineGene FrequencyInternal medicineSurveys and QuestionnairesSeverity of illnessmedicineHumansAlleleSex DistributionPsychiatryAllele frequencyGenetic associationDNA PrimersDemographyAuditory hallucinationPolymorphism Geneticmedicine.diseaseIntrons030227 psychiatryReceptor Cholecystokinin ADiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthEndocrinologySchizophreniaSchizophreniaFemalemedicine.symptomPsychology030217 neurology & neurosurgeryEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular & Hematological Disorders-Drug Targets
researchProduct

Cervical Spondylotic Myelopathy: When and Why the Cervical Corpectomy?

2020

Background: Cervical spondylotic myelopathy (CSM) is a degenerative disease that represents the most common spinal cord disorder in adults. The best treatment option has remained controversial. We performed a prospective study to evaluate the clinical, radiographic, and neurophysiologic outcomes for anterior cervical corpectomy in the treatment of CSM. Methods: From January 2011 to January 2017, 60 patients with CSM were prospectively enrolled in the present study. The patients were divided according to the modified Japanese Orthopaedic Association scale (mJOA) score into 2 groups: group A, patients with mild to moderate CSM (mJOA score ≥13); and group B, patients with severe myelopathy (mJ…

AdultMalemedicine.medical_specialtyRadiographymedicine.medical_treatmentSpinal Cord DisorderIntervertebral Disc DegenerationOssification of Posterior Longitudinal LigamentSeverity of Illness IndexMyelopathyYoung AdultDegenerative diseaseSpondylotic myelopathySymptom durationMedicineHumansProspective StudiesCorpectomyProspective cohort studyCervical corpectomy Young Adult Cervical spondylotic myelopathy Degenerative cervical myelopathy Surgical outcomes Adult Aged Cervical Vertebrae Decompression Surgical Functional Status Intervertebral Disc Degeneration Female Intervertebral Disc Displacement Humans Ossification of Posterior Longitudinal Ligament Middle Aged Male Prospective Studies Spinal Cord Compression Severity of Illness Index Treatment Outcome Spinal Fusion SpondylosisAgedbusiness.industryMiddle Agedmedicine.diseaseDecompression SurgicalSurgeryFunctional StatusSpinal FusionTreatment OutcomeCervical VertebraeSurgeryFemaleNeurology (clinical)SpondylosisbusinessSpinal Cord CompressionIntervertebral Disc DisplacementWorld neurosurgery
researchProduct

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet (R)) versus calcipotriol (Daivonex (R)) in the treatment of …

2007

Objective: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet (R)) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex (R)) alone for 12 weeks (group B) for the treatment of psoriasis. Materials and methods: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. Results: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher c…

AdultMalemedicine.medical_specialtyRandomizationAdolescentskindex-29medicine.drug_classBetamethasone dipropionatecalcipotriol/betamethasone dipropionate; Dovobet; calcipotriol. Daivonex; psoriasis vulgaris; clinical trialDermatologyAdministration CutaneousBetamethasoneSeverity of Illness IndexDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialCalcitriolcalcipotriolo/betametasone dipropionatolawPsoriasisInternal medicinepasimedicineHumansPsoriasiscalcipotriolo; calcipotriolo/betametasone dipropionato; pasi; psoriasi; skindex-29CalcipotriolcalcipotriolopsoriasiAgedAged 80 and overAnalysis of Variancebusiness.industrycalcipotriol calcipotriol/betamethasone dipropionate PASI psoriasis Skindex-29 two-compound productMiddle Agedmedicine.diseaseSurgeryClinical trialDrug CombinationsTreatment OutcomechemistryQuality of LifeCorticosteroidBetamethasoneFemaleDermatologic Agentsbusinessmedicine.drug
researchProduct

Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids

2008

Abstract Background Thrombosed external haemorrhoids are one of the most frequent anorectal emergencies. They are associated with swelling and intense pain. Internal sphincter hypertonicity plays a role in the aetiology of the pain. This study evaluated the efficacy and safety of an intrasphincteric injection of botulinum toxin for pain relief in patients with thrombosed external haemorrhoids. Methods Thirty patients with thrombosed external haemorrhoids who refused surgical operation were randomized into two groups. Patients received an intrasphincteric injection of either 0·6 ml saline or 0·6 ml of a solution containing 30 units botulinum toxin. Anorectal manometry was performed before tr…

AdultMalemedicine.medical_specialtyRandomizationAnal CanalPainInjections IntralesionalHemorrhoidsSeverity of Illness Indexlaw.inventionRandomized controlled triallawmedicineHumansbotulinum toxinBotulinum Toxins Type APain MeasurementAnalgesicsVascular diseasebusiness.industryUrethral sphincterAnorectal manometryThrombosisAnal canalmedicine.diseaseBotulinum toxinSurgeryClinical trialTreatment Outcomemedicine.anatomical_structureNeuromuscular AgentsFemaleSurgerybusinessmedicine.drugBritish Journal of Surgery
researchProduct

A Comparison of Five Maintenance Therapies for Reflux Esophagitis

1995

Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride (10 mg three times a day), or …

AdultMalemedicine.medical_specialtyRanitidineSeverity of Illness IndexGastroenterologyDisease-Free SurvivalRanitidinePiperidinesRecurrenceInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesReflux esophagitisProspective cohort studyEsophagitis PepticOmeprazoleCisapridemedicine.diagnostic_testEsophageal diseasebusiness.industryGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseaseSurgeryEndoscopyTreatment OutcomeHistamine H2 AntagonistsCisaprideDrug Therapy CombinationFemaleEsophagoscopybusinessEsophagitisOmeprazolemedicine.drugNew England Journal of Medicine
researchProduct

Effects of REM sleep awakenings and related wakening paradigms on the ultradian sleep cycle and the symptoms in depression.

2002

In 1975 Vogel and coworkers published their classical study where they compared selective rapid eye movement (REM) sleep deprivation by brief awakenings to a control intervention paradigm in depressed patients. The superior antidepressive impact of the first procedure was attributed to the REM pressure accumulating during the treatment period. The laborious procedure and the considerable effort necessary to evaluate the sleep profiles in real time have prevented similar experiments so far. Based on artificial neural networks we developed a software for the real time detection of REM sleep. In combination with an alarm system the algorithm allowed us to wake up subjects automatically and to …

AdultMalemedicine.medical_specialtyRapid eye movement sleepSleep REMAudiologyAntidepressive Agents TricyclicNon-rapid eye movement sleepSeverity of Illness IndexSleep Disorders Circadian RhythmSurveys and QuestionnairesmedicineHumansCircadian rhythmWakefulnessPsychiatryBiological PsychiatryUltradian rhythmSlow-wave sleepDepressionTrimipramineTrimipramineSleep in non-human animalsCircadian RhythmPsychiatry and Mental healthSleep deprivationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.

2009

Abstract Background: To assess criteria and to identify predictive factors for functional outcome. The criteria should cover all domains proposed by the Remission in Schizophrenia Working Group. Method: PANSS ratings were used to evaluate the symptomatic treatment outcome of 262 inpatients with schizophrenia spectrum disorders within a naturalistic multicenter trial. Functional remission was defined as a GAF score > 61 (Global Assessment of Functioning Scale), SOFAS score > 61 (Social and Occupational Functioning Scale) and a SF-36 mental health subscore > 40 (Medical Outcomes Study—Short Form Health Survey). Multivariate logistic regression and CART analyses were used to determine valid cl…

AdultMalemedicine.medical_specialtySF-36Global Assessment of FunctioningNeuropsychological TestsLogistic regressionSeverity of Illness IndexDevelopmental psychology03 medical and health sciencesYoung Adult0302 clinical medicinePredictive Value of TestsRecurrenceInternal medicineMulticenter trialSeverity of illnessOutcome Assessment Health CaremedicineHumansBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesMiddle Agedmedicine.disease030227 psychiatry3. Good healthPsychiatry and Mental healthPsychotic DisordersROC CurveSchizophreniaPredictive value of testsSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychologyPsychosocial030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia research
researchProduct